Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halberd Corp (OP: HALB )

0.0036 -0.0003 (-7.69%)
Streaming Delayed Price Updated: 3:58 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halberd Corp

< Previous 1 2 3 4 5 Next >
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp, Featured on The Street Reports Podcast
Via ACCESSWIRE
Halberd's Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
Via ACCESSWIRE
Penny Stocks On The Move: HALB, NHMD, IFUS, GSTC
Via AB Newswire
Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
Via ACCESSWIRE
Astounding Early Test Results of Halberd's Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
Via ACCESSWIRE
Exploring the Top Sub-Penny Stocks to Watch Now: HALB, SIRC, AITX, MWWC, HRAL
Via AB Newswire
Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Via ACCESSWIRE
Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
Via ACCESSWIRE
Halberd Corporation 2Q23 CEO Letter
Via ACCESSWIRE
Canna America (OTC:CNNA) Hits New Highs “Similar Patterns Revealed”: HALB, AITX, HMBL, DPLS
Via AB Newswire
Halberd CEO Mid-Quarter Update
Via ACCESSWIRE
Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
Via ACCESSWIRE
The Street Reports Podcast Hosts Halberd Corp (HALB), Houston Natural Resources (HNRC), Marketing Worldwide (MWWC), Defense Technologies (DTII), PlantX Life (PLTXF) (VEGA.C)
Via AB Newswire
Halberd Pre-Clinical Test Protocol Approved
Via ACCESSWIRE
Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
Via ACCESSWIRE
Halberd Corporation 1Q23 CEO Letter
Via ACCESSWIRE
Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens
Via ACCESSWIRE
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
Via ACCESSWIRE
HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC, Research Discoveries etc., on "The Street Reports Podcasts" Listen Now!
Via ACCESSWIRE
Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances
Via ACCESSWIRE
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
Via ACCESSWIRE
Halberd's Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens
Via ACCESSWIRE
Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma
Via ACCESSWIRE
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Via ACCESSWIRE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Via ACCESSWIRE
Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma
Via ACCESSWIRE
Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University
Via ACCESSWIRE
Halberd Agrees to Animal Testing at Mississippi State University
Via ACCESSWIRE
Halberd Corporation 2022 Year End CEO Letter and 2023 Goals
Via ACCESSWIRE
Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.